Effect of nedocromil on antigen-induced bronchoconstriction in asthmatic subjects

N. Nair, R. J. Hopp, R. Townley

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Nedocromil sodium, a pyranoquinoline decarboxylic acid derivative, is a new antiasthma compound undergoing clinical investigation. It has been shown to be effective in the management of asthma and to attenuate exercise-induced bronchoconstriction. We performed a randomized, double-blind, placebo-controlled, crossover study in 12 ragweed-sensitive subjects known to respond to inhaled ragweed antigen. On two study days, four to ten days apart, ragweed challenges were performed using a standard protocol 30 minutes after a single dose (two puffs of 2 mg/puff) of either active drug or placebo. The PD20 (20% fall in FEV1) for each treatment day was compared by parametric and nonparametric 2-period crossover analyses. Baseline FEV1 pre-drug and post-drug administration did not differ significantly between study days. On the nedocromil day, the mean ± SD for log PD20 was 2.25 ± 0.561 and on the placebo day, 1.73 ± 1.048 (P = 0.04). There were no side effects associated with either treatment. These results demonstrate that nedocromil is effective in shifting the stimulus response curve to inhaled antigen in some ragweed-sensitive subjects. Its wide spectrum of efficacy against bronchoprovocation suggests it is useful in the treatment of hyperreactive airway disorders.

Original languageEnglish
Pages (from-to)329-331
Number of pages3
JournalAnnals of Allergy
Volume62
Issue number4
StatePublished - 1989

Fingerprint

Nedocromil
Ambrosia
Bronchoconstriction
Antigens
Placebos
Pharmaceutical Preparations
Cross-Over Studies
Therapeutics
Asthma
Demography
Acids

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy

Cite this

Effect of nedocromil on antigen-induced bronchoconstriction in asthmatic subjects. / Nair, N.; Hopp, R. J.; Townley, R.

In: Annals of Allergy, Vol. 62, No. 4, 1989, p. 329-331.

Research output: Contribution to journalArticle

Nair, N, Hopp, RJ & Townley, R 1989, 'Effect of nedocromil on antigen-induced bronchoconstriction in asthmatic subjects', Annals of Allergy, vol. 62, no. 4, pp. 329-331.
Nair, N. ; Hopp, R. J. ; Townley, R. / Effect of nedocromil on antigen-induced bronchoconstriction in asthmatic subjects. In: Annals of Allergy. 1989 ; Vol. 62, No. 4. pp. 329-331.
@article{e7b9ad55819a4188b4fe1d1c9e031ab3,
title = "Effect of nedocromil on antigen-induced bronchoconstriction in asthmatic subjects",
abstract = "Nedocromil sodium, a pyranoquinoline decarboxylic acid derivative, is a new antiasthma compound undergoing clinical investigation. It has been shown to be effective in the management of asthma and to attenuate exercise-induced bronchoconstriction. We performed a randomized, double-blind, placebo-controlled, crossover study in 12 ragweed-sensitive subjects known to respond to inhaled ragweed antigen. On two study days, four to ten days apart, ragweed challenges were performed using a standard protocol 30 minutes after a single dose (two puffs of 2 mg/puff) of either active drug or placebo. The PD20 (20{\%} fall in FEV1) for each treatment day was compared by parametric and nonparametric 2-period crossover analyses. Baseline FEV1 pre-drug and post-drug administration did not differ significantly between study days. On the nedocromil day, the mean ± SD for log PD20 was 2.25 ± 0.561 and on the placebo day, 1.73 ± 1.048 (P = 0.04). There were no side effects associated with either treatment. These results demonstrate that nedocromil is effective in shifting the stimulus response curve to inhaled antigen in some ragweed-sensitive subjects. Its wide spectrum of efficacy against bronchoprovocation suggests it is useful in the treatment of hyperreactive airway disorders.",
author = "N. Nair and Hopp, {R. J.} and R. Townley",
year = "1989",
language = "English",
volume = "62",
pages = "329--331",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "4",

}

TY - JOUR

T1 - Effect of nedocromil on antigen-induced bronchoconstriction in asthmatic subjects

AU - Nair, N.

AU - Hopp, R. J.

AU - Townley, R.

PY - 1989

Y1 - 1989

N2 - Nedocromil sodium, a pyranoquinoline decarboxylic acid derivative, is a new antiasthma compound undergoing clinical investigation. It has been shown to be effective in the management of asthma and to attenuate exercise-induced bronchoconstriction. We performed a randomized, double-blind, placebo-controlled, crossover study in 12 ragweed-sensitive subjects known to respond to inhaled ragweed antigen. On two study days, four to ten days apart, ragweed challenges were performed using a standard protocol 30 minutes after a single dose (two puffs of 2 mg/puff) of either active drug or placebo. The PD20 (20% fall in FEV1) for each treatment day was compared by parametric and nonparametric 2-period crossover analyses. Baseline FEV1 pre-drug and post-drug administration did not differ significantly between study days. On the nedocromil day, the mean ± SD for log PD20 was 2.25 ± 0.561 and on the placebo day, 1.73 ± 1.048 (P = 0.04). There were no side effects associated with either treatment. These results demonstrate that nedocromil is effective in shifting the stimulus response curve to inhaled antigen in some ragweed-sensitive subjects. Its wide spectrum of efficacy against bronchoprovocation suggests it is useful in the treatment of hyperreactive airway disorders.

AB - Nedocromil sodium, a pyranoquinoline decarboxylic acid derivative, is a new antiasthma compound undergoing clinical investigation. It has been shown to be effective in the management of asthma and to attenuate exercise-induced bronchoconstriction. We performed a randomized, double-blind, placebo-controlled, crossover study in 12 ragweed-sensitive subjects known to respond to inhaled ragweed antigen. On two study days, four to ten days apart, ragweed challenges were performed using a standard protocol 30 minutes after a single dose (two puffs of 2 mg/puff) of either active drug or placebo. The PD20 (20% fall in FEV1) for each treatment day was compared by parametric and nonparametric 2-period crossover analyses. Baseline FEV1 pre-drug and post-drug administration did not differ significantly between study days. On the nedocromil day, the mean ± SD for log PD20 was 2.25 ± 0.561 and on the placebo day, 1.73 ± 1.048 (P = 0.04). There were no side effects associated with either treatment. These results demonstrate that nedocromil is effective in shifting the stimulus response curve to inhaled antigen in some ragweed-sensitive subjects. Its wide spectrum of efficacy against bronchoprovocation suggests it is useful in the treatment of hyperreactive airway disorders.

UR - http://www.scopus.com/inward/record.url?scp=0024589850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024589850&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 329

EP - 331

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 4

ER -